An ointment (Elase® or Fibrolan®) containing bovine DNase I and bovine fibrinolysin has been used clinically as a debriding agent in a variety of inflammatory and infected lesions . The combination of these two enzymes was based on the observation that purulent exudates of infected lesions consist largely of fibrinous material and DNA. The ointment improved the healing of infected accidental or surgical wounds , ulcerative lesions [157,158], and second- and third-degree burns . However, in the late 1990s, in vitro and placebo-controlled studies clearly showed that Elase was not significantly more effective than a placebo ointment [160-162]. This led to the withdrawal of the ointment from the American market in 1999.
DNases have also been evaluated in the treatment of cancer. Linardou, et al.  made a fusion protein by combining bovine DNase I and a single-chain Fv fragment of an antibody directed to tumor-specific antigens. The obtained chimeric protein was highly cytotoxic in vitro in tumor cells expressing the antigen . Recently, a more potent and human-based chimeric protein comprising gonadotropin-releasing hormone as a tumortargeting moiety and CAD as a cytotoxic moiety caused a targeted killing of adenocarci-noma cells in vitro and in mice .
Was this article helpful?